On being a good doctor. The number of research publications don’t tell you how good a doctor is at being a doctor. Neither do the number of book chapters or grants. Or academic rank. It’s a different skill set. Good doctors have stellar clinical acumen & empathy. #MedTwitter

Why not Dara maintenance? No data that Dara maintenance adds significant benefit if Dara was given at induction. See Cassiopeia below. Given cost and long term risks, we need clear data that patients who received quad induction get benefit from Dara maintenance. #ASH23 6/

All you need to know about Essential Thrombocythemia — an excellent review by the master in the field, Dr. Ayalew Tefferi. Crystal clear writing that only a true expert can do. #MedTwitter onlinelibrary.wiley.com/doi/10.1002/aj…

1/8 🤔Why is pulmonary embolism (PE) so rare in Behçet Syndrome? The condition is associated with a 14-fold increased risk of deep vein thrombosis (DVT) but almost none of these result in PE. What is it about the thrombus in Behçet that makes it so unable to embolize?

Instilling hope for patients with relapsed AL amyloidosis: Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series ashpublications.org/blood/article-…

Smoldering myeloma with m protein 2.5 in 2006. What treatment did she get? Nothing. Only tincture of time. #myeloma. A lot to learn about you.

Great slide Craig Hofmeister on monoclonal gammopathies of clinical significance. Bookmark. #MedTwitter Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Luciano J Costa

Adverse event spectrum and severity with tyrosine kinase inhibitors thelancet.com/journals/lance…

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia ow.ly/3Vba50Roppr #HowITreat #lymphoidneoplasia

Ten important observations about myeloma and its precursors that I often discuss with patients and teach to trainees in my clinic. An educational thread 🧵 #mmsm 1/

Lovely letter to the editor on when you should test for BCR/ABL in a patient w/ high neutrophils. Like so many things in hematology, the answer is "far less often than you think." Thank you for amplifying, Bloodman! #Minimalist #Stewardship

Congrats on excellent and novel work David Su on surgical outcomes with the use of heme e-consults!

I’m excited to share that my latest review article on AL amyloidosis is now published in the New England Journal of Medicine! BU Amyloidosis Center Boston U Chobanian & Avedisian School of Medicine Boston Medical Center Systemic Light Chain Amyloidosis | New England Journal of Medicine nejm.org/doi/pdf/10.105…

FDA approves Dara-VRd for newly diagnosed myeloma. Quads have become standard of care. Based on 4 phase III trials I recommend Quads for all newly diagnosed patients except those who are frail. See thread. fda.gov/drugs/resource…

A patient with serious thrombotic episodes was found to have a monoclonal gammopathy of an anti–PF4 antibody. Myeloma therapy reduced the paraprotein level and prevented further thrombotic events. Read the full correspondence: nej.md/3SFWdsN

PO vs IM Vitamin B12 You have a patient with newly diagnosed pernicious anemia (otherwise well), who has received appropriate initial treatment with IM B12. You explain to them they need lifelong B12 replacement. They ask whether they can take it orally. What is your answer?

Bob Salata was the kind of doctor you hope for a loved one when sick. As a chief resident of Dr Salata’s while he was chair, he knew half of medical care, including many emergencies, occur overnight. He spent the 8pm-midnight hours one night rounding with and teaching interns.

#Myeloma Paper of the Day: #MGUS risk stratification models can be applied longitudinally to repeatedly determine & improve individual risk of progression, w/ patients who get upstaged to a high-risk category having increased chance of progression: pubmed.ncbi.nlm.nih.gov/39191769/. #mmsm

BIG NEWS in Ontario Canada today as ALL major community laboratories switch to clinical decision limits for ferritin in diagnosing iron deficiency. <30 ug/L for adults <20 ug/L for children 👏🏽👏🏽👏🏽👏🏽👏🏽👏🏽👏🏽👏🏽👏🏽👏🏽👏🏽👏🏽

Rituximab refractory or intolerant immune TTP cases are very difficult to manage. Paper in British Journal of Haematology from France suggest that Daratumumab is a reasonable therapeutic option. tinyurl.com/59p7ybwt #TTP #daratumumab